secwatch.observer — SEC 8-K summary
======================================

Issuer:     Centessa Pharmaceuticals plc (CNTA)
CIK:        0001847903
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0001847903-25-000069
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Centessa Q1 net loss $26.1M; cash $424.9M; OX2R agonist pipeline on track for 2025 data
--------------------------------------------------------------------------------

- Net loss narrowed to $26.1M from $38.0M in Q1 2024, with no product revenue.
- Cash, equivalents and investments totaled $424.9M, expected to fund operations into mid-2027.
- R&D expenses increased to $33.4M from $22.7M, driven by pipeline advancement.
- ORX750 Phase 2a CRYSTAL-1 study ongoing; data from narcolepsy NT1, NT2 and IH anticipated in 2025.
- ORX142 first-in-human studies planned in 2025 with data from sleep-deprived healthy volunteers expected.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847903/000184790325000069/0001847903-25-000069-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847903/000184790325000069/cnta-20250514.htm
  HTML page:      https://secwatch.observer/filing/0001847903-25-000069

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer